Sagimet Biosciences to Participate in the First Annual Goldman Sachs Catalyst Clinic
04 déc. 2023 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences Announces Oral Presentation of Preclinical Results of FASN Inhibitor in Combination with Semaglutide at the 7th Obesity and NASH Drug Development Summit
28 nov. 2023 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
22 nov. 2023 08h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN)...
Sagimet Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
13 nov. 2023 08h00 HE
|
Sagimet Biosciences Inc.
On track to report topline week 52 liver biopsy results from Phase 2b FASCINATE-2 trial with denifanstat in the first quarter of 2024 Two abstracts, including late-breaker, accepted at the American...
Sagimet Biosciences Presents Preclinical Results Supporting the Therapeutic Potential of its FASN inhibitor in Combination with Semaglutide and a Comprehensive Lipidomic Analysis of Interim FASCINATE-2 Data at AASLD - The Liver Meeting® 2023
10 nov. 2023 08h30 HE
|
Sagimet Biosciences Inc.
Combination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a mouse model and showed a significant improvement in liver...
Sagimet Biosciences Announces Acceptance of Two Abstracts at AASLD - The Liver Meeting® 2023
24 oct. 2023 11h00 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
Sagimet Biosciences To Present at the H.C. Wainwright 7th Annual NASH Investor Conference
18 oct. 2023 16h05 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that...
Sagimet Biosciences Announces Completion of Enrollment of 120 Patients for Phase 3 Clinical Trial by Its Partner Ascletis of Denifanstat Combined with Bevacizumab for Treatment of Recurrent Glioblastoma
27 sept. 2023 16h05 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional...
Sagimet Biosciences Reports Second Quarter 2023 Financial Results and Provides Corporate Updates
21 août 2023 16h02 HE
|
Sagimet Biosciences Inc.
Completed upsized initial public offering raising $96.4 million in gross proceeds Presented positive data at EASL Congress 2023 from the planned interim readout of the Phase 2b FASCINATE-2 trial in...
Sagimet Biosciences Announces Closing of Underwriters’ Option to Purchase Additional Shares of Series A Common Stock in Connection with its Upsized Initial Public Offering
15 août 2023 16h04 HE
|
Sagimet Biosciences Inc.
SAN MATEO, Calif., Aug. 15, 2023 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting...